Blue­print­'s long­time CEO pre­pares to step down as biotech rev­els in new Ay­vak­it launch, pipeline ex­pan­sion

Af­ter a busy 2021 brought Blue­print Med­i­cines its fourth FDA ap­proval, the com­pa­ny is kick­ing off the new year with plans to shake up its C-suite.

Jeff Al­bers, Blue­print’s CEO for the past eight years, will be step­ping down April 4 and tran­si­tion­ing to the ex­ec­u­tive chair­man po­si­tion, the biotech an­nounced Wednes­day morn­ing. He will be re­placed by COO Kate Hav­i­land, who moves in­to both the chief ex­ec­u­tive and pres­i­dent roles. Christi­na Rossi al­so nabs a pro­mo­tion from chief com­mer­cial of­fi­cer to COO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER